Yemen leader announces major military operations against Iran-backed Houthis
The leader of Yemen's Saudi-backed government announced the beginning of a major military operation against...
AstraZeneca is acquiring Belgium-based EsoBiotec for $1 billion to expand its cell therapy capabilities, with the deal set to close in the second quarter.
AstraZeneca, the British-Swedish pharmaceutical and biotechnology joint venture, announced on Monday that it has reached an agreement to acquire EsoBiotec, according to a company press release.
The Belgium-based biotech firm has accepted AstraZeneca's $1 billion acquisition offer for its entire shareholding, with an initial payment of $425 million.
The deal is expected to be finalised in the second quarter of this year, subject to regulatory approvals and customary closing conditions.
"EsoBiotec will enhance and build upon the impact of our recent investments, representing a significant step towards realising our ambition to fully harness the potential of cell therapy," said Susan Galbraith, AstraZeneca's Executive Vice President.
Jean-Pierre Latere, CEO of EsoBiotec, stated: "We are excited to collaborate with AstraZeneca, a global leader in drug development, to advance our shared goal of delivering cost-effective, transformative cell therapies to a wider patient population. By combining our expertise and resources, we can accelerate the development of our in vivo platform, which utilises an innovative delivery technology with broad therapeutic potential."
EsoBiotec is a pioneering biotechnology company specialising in in vivo cell therapies for cancer, with early clinical studies showing promising results.
The company's Engineered NanoBody Lentiviral platform enhances the immune system's ability to combat cancer and has the potential to make cell therapy more accessible, reducing treatment times from weeks to just minutes.
The co-pilot of Israel bound flydubai flight attempted to carry out a “terrorist attack” with an axe during the flight, the United Arab Emirates prosecutor general said on Saturday.
Hammam al-Hammami, the Flydubai co-pilot accused of stabbing the captain of an Israel-bound flight on Wednesday in a suspected terrorist attack, was banned from flying by Oman over concerns about his radical views, U.S. media reported on Friday, citing people familiar with the matter.
Two Iranian nationals have been charged in Britain with preparing a suspected terrorist attack targeting the Jewish community in northern England, police said on Friday (2 October).
A major bridge across the Dnipro river in Kyiv was hit in a Russian air attack on Saturday, the city's mayor, Vitali Klitschko said, as strikes on the capital's infrastructure continue.
Uzbekistan’s grape exports have grown rapidly. In January-August 2025, the country exported 86,200 tonnes of fresh grapes worth $78.3 million to 19 countries but can it turn these crops into a recognisable international product?
Health advice now reaches people through social media, fitness apps, wearable technology and AI. From detoxes and protein-focused diets to skincare and fitness trends, online wellness content is shaping everyday health choices while raising concerns about misinformation and potential risks.
Global cholera deaths reached their highest annual level in more than 20 years in 2025, despite a decline in reported cases, according to the World Health Organization (WHO).
Chinese researchers have developed the world’s smallest CT scanner, a portable device designed to produce images of tiny fossils and archaeological relics.
Here's your AnewZ Daily Brief for 17 September 2026. These are the top five stories making headlines in the field of health.
Doctors in St. Louis have successfully separated Ethiopian two-year-old twin girls who were born joined at the head after a months-long series of complex operations culminating in a nearly 25-hour final procedure, doctors said on Wednesday.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment